You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • S100 Cumulative distribution of patients by change in FVC% predicted in the inpulsis® trials of NINTEDANIB in patients with idiopathic pulmonary fibrosis

Article Text

Article menu
Download PDFPDF
Idiopathic Pulmonary Fibrosis Therapy
S100 Cumulative distribution of patients by change in FVC% predicted in the inpulsis® trials of NINTEDANIB in patients with idiopathic pulmonary fibrosis
  1. U Costabel1,
  2. KR Flaherty2,
  3. KK Brown3,
  4. W Stansen4,
  5. R Schlenker-Herceg5,
  6. G Raghu6
  1. 1Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany
  2. 2University of Michigan Health System, Ann Arbor, USA
  3. 3National Jewish Health, Denver, USA
  4. 4Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim am Rhein, Germany
  5. 5Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA
  6. 6University of Washington, Seattle, USA

Abstract

Introduction The two 52-week Phase III INPULSIS® trials assessed the efficacy and safety of nintedanib in patients with IPF. In both trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo.

Methods We assessed the cumulative distribution of patients by absolute changes from baseline to week 52 in FVC% predicted using thresholds of ≥0%, ≥5% and ≥10% in the individual INPULSIS® trials and pooled data. Missing data (due to death, loss to follow-up, or censoring before week 52) were imputed using the worst decline from baseline at week 52 observed in all patients with available data regardless of treatment.

Results 1061 patients were treated in the INPULSIS® trials (n = 638 nintedanib; n = 423 placebo). In INPULSIS®−1, a smaller proportion of patients treated with nintedanib than placebo had any decline in FVC% predicted (absolute decline in FVC ≥ 0% predicted) (71% versus 82%; p = 0.002), an absolute decline in FVC ≥ 5% predicted (47% versus 62%; p = 0.001) and an absolute decline in FVC ≥ 10% predicted (29% versus 43%; p < 0.001) from baseline to week 52 based on the cumulative distribution of patients. In INPULSIS®−2, a smaller proportion of patients treated with nintedanib than placebo had any decline in FVC% predicted (70% versus 88%; p < 0.001), an absolute decline in FVC ≥ 5% predicted (47% versus 61%; p = 0.001) and an absolute decline in FVC ≥ 10% predicted (30% versus 36%; p = 0.18) from baseline to week 52. In pooled data, the proportions of patients treated with nintedanib and placebo, respectively, who had any decline in FVC ≥ 0% predicted, an absolute decline in FVC ≥ 5% predicted and an absolute decline in FVC ≥ 10% predicted were 70% versus 85% (p < 0.001), 47% versus 61% (p < 0.001) and 30% versus 39% (p < 0.001) (Figure). The proportion of patients with no decline or an improvement in FVC% predicted were 30% in the nintedanib group versus 15% in the placebo group.

Conclusion In the INPULSIS® trials, a higher proportion of patients with IPF treated with nintedanib than placebo had no decline or an improvement in FVC. Smaller proportions of patients had absolute declines in ≥5% and ≥10% predicted over 52 weeks.

Abstract S100 Figure 1
Abstract S100 Figure 1

https://doi.org/10.1136/thoraxjnl-2016-209333.106

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.